PanOptica

Risk score

57
Large logo of PanOptica

Headquarters

Flag of United States of AmericaUnited States of America

PanOptica strives to overcome the constraints of current treatments for severe ophthalmic conditions by creating a topical eye drop substitute for intravitreal (back-of-the eye) injection therapies. PanOptica, Inc., is a private, clinical-stage biopharmaceutical company dedicated to developing a topical eye drop for treating vision-endangering eye ailments resulting from abnormal or leaking blood vessels. These neovascular eye conditions encompass neovascular age-related macular degeneration (wet AMD), the primary cause of vision loss in the Western world, and diabetic retinopathy.